Hematopoietic stem cell transplantation (HSCT) represents a curative option for those afflicted with numerous hematologic malignancies and bone marrow failure syndromes. Advances and refinement of the HSCT process have resulted in increasing number of transplants performed on older patients in the recent years. Pre-transplant assessments (PTA) function to risk stratify patients prior to undergoing HSCT in an effort to predict those at higher risk of treatment-related toxicity, to inform risk/benefit assessments and to aid clinical decision making. Traditionally used risk stratification parameters such as chronologic age, comorbidity and performance status may not fully capture physical function, physiologic fitness, highlighting a need for improvement in PTA. Incorporation of frailty measurements in pre-HSCT assessments, particularly in elderly transplant candidates, may result in improving predictive ability of existing tools such as the Hematopoietic Cell Transplantation Comorbidity Index and Karnofsky performance status. Here, we review existing pre-HSCT assessment tools, measures of frailty that may aid in risk stratification for patients undergoing HSCT and directions for future research using frailty in the pre-HSCT setting.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a potential curative treatment for malignant hematologic diseases such as myelodysplastic syndrome, leukemia, lymphoma and myeloma. The number of older individuals undergoing HSCT for malignant disease has risen considerably. Between 2007 and 2013, 22% of allogeneic transplants and 44% of autologous transplants were in patients older than 60 years of age.
1 This can be attributed to the reduction in treatment-related mortality through the use of reduced intensity conditioning (RIC) regimen in allogeneic HSCT and advances in post-HSCT supportive care.
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The elderly have been shown to benefit from HSCT. While chronologic age alone has been shown to be a poor predictor of non-relapse mortality (NRM), disease-free survival and overall survival (OS), 2,5-8 older age increases the odds for non-referral to HSCT. A national survey of hematologists/ medical oncologists reported that 92% of respondents were influenced in their decision for HSCT referral by patient age, while 48% reported co-morbidities and 57% reported social support as influential factors. 9 Older age also serves as a barrier to clinical trials enrolment in HSCT. Based on NIH clinical trial registry of elderly patients, 90% of HSCT clinical trials excluded older individuals (475 years), with 75% of those based on chronologic age only. 10 Inadequate accrual remains a problem even for trials that allow older patients, mostly due to physician reluctance, comorbidities and performance status. 11 Better risk stratification is essential as OS in elderly HSCT recipients remains modest despite improvements with RIC regimen. 2, 6, 7, 12 Although there has been a decline in NRM due to drug toxicities, infections and chronic GVHD (cGVHD) with RIC regimen as well as improved post-HSCT supportive care, long-term NRM in the elderly remains upwards of 20%. 2, 6, 7, 12 As poor risk cytogenetics that portend increased rate of relapse tend to occur more frequently in older patients with hematologic malignancies, long-term relapse rate in the elderly following allogeneic HSCT with RIC remains upwards of 30% and diseasefree survival remains low. 2, 6, 7, 13, 14 HSCT survivors of all ages are at risk for developing frailty, which has been defined as 'a medical syndrome with multiple causes and contributors that is characterized by diminished strength, endurance, and reduced physiologic function that increases an individual's vulnerability for developing increased dependency and/or death.' 15 Exposure to high intensity chemotherapy and cGVHD in HSCT recipients are risk factors for frailty. 16, 17 In HSCT recipients across all ages, frailty is both prevalent and associated with adverse outcomes. Traditionally used pre-transplant assessments (PTA) parameters such as chronologic age, comorbidity indices and performance status may not detect the presence of frailty. Hence, incorporation of frailty assessment may optimize the predictive ability of existing PTA tools across all age groups and particularly in elderly individuals.
Frailty syndrome in HSCT recipients
Prevalence and risk factors. Frailty is largely known and studied as a geriatric syndrome in the general population with a prevalence of around 10% in community dwelling individuals aged 65 years and above. 18 However, frailty is prevalent across all ages of HSCT recipients. Pre-HSCT prevalence in patients ⩾ 50 years of age is higher than in the general geriatric population at around 25%. 19, 20 In another prospective study of HSCT recipients aged ⩾ 40 years, the prevalence of frailty before HSCT was 8% and increased to 39% at 6 months post-HSCT. 21 Frailty is also prevalent several years post-HSCT at 13 and 8.4% among patients aged ⩾ 65 years and 18-64 years respectively. 17, 22 As a result of prior chemotherapy, conditioning regimen and cGVHD, HSCT recipients are at risk of accelerated physiologic aging and hence frailty. 16, [23] [24] [25] In a prospective study comparing health-related quality of life of patients undergoing allogeneic transplant with myeloablative conditioning or RIC, more than 20% of patients in both cohorts reported that various components of health-related quality of life including physical functioning and fatigue, continued to be worse than baseline at 12 months. 26 Reduced physical functioning and fatigue associated with cGVHD also lead to frailty. [27] [28] [29] In one study of elderly patients (⩾65 years), recipients of allogeneic HSCT with cGVHD were 2.7 times more likely to report frailty as compared with autologous HSCT recipients. 17 Among HSCT recipients aged 18-64 years, those with active cGVHD were 15 times more likely and even those with resolved cGVHD were 2.7 times more likely to be frail when compared to autologous HSCT recipients. 22 Importantly, in all studies, age had no effect on the prevalence of frailty. Therefore, it is important to identify frailty during PTA in all HSCT recipients and especially in the elderly.
Impact on HSCT outcomes. Frailty in the pre-HSCT setting is associated with poor outcomes in both young and old individuals. In allogeneic HSCT recipients ⩾ 50 years of age, after adjusting for various factors including age, Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) and disease risk, markers of frailty were associated with worse OS and NRM. 20 In all HSCT recipients aged ⩾ 40 years, frailty was associated with a trend towards higher 1-year NRM. 21 Pre-HSCT frailty assessment may provide additional data regarding the physiologic age of an individual and optimize existing PTA tools.
Frailty and standard pre-transplant assessment tools The HCT-CI is one of the most widely used comorbidity scales in PTA. 30 Increasing HCT-CI scores are associated with higher NRM and OS, irrespective of conditioning regimen and type of HSCT (allogeneic and autologous). [30] [31] [32] However, when controlled for all other risk factors, including comorbidities, increasing age is still significantly associated with higher NRM. 33 Frailty is associated with poor OS even after adjusting for age and HCT-CI. 20 Frailty assessment in addition to HCT-CI may further improve our ability to risk stratify individuals.
Although studies evaluating the ability of performance status measures to predict HSCT outcomes are scarce, the Karnofsky performance status (KPS) and eastern cooperative oncology group (ECOG) performance status scores are commonly used in pre-HSCT evaluation. Poor KPS and ECOG performance status scores are associated with higher transplant-related mortality and worse OS. 34, 35 However, the KPS and ECOG scores are both subjective assessments made by physicians. They do not involve a questionnaire and lack definitions for assessment of various domains of the scales. Both scores are prone to inter-observer variability. [36] [37] [38] There is only moderate correlation between physician and patient reported performance status, with patients scoring themselves more pessimistically than their physicians. [39] [40] [41] In cancer patients, discordance between physician assessed and patient assessed performance status is associated with worse survival. 42, 43 These factors decrease the sensitivity of performance status scores in predicting adverse health outcomes. Frailty assessment may provide more sensitive measure of functional status.
Disease relapse is a significant factor affecting HSCT outcomes. The Disease Risk Index (DRI) combines disease risk and disease status prior to HSCT to categorize patients as low, intermediate, high or very high risk. Irrespective of age and conditioning regimen, the DRI was shown to successfully predict OS and incidence of relapse but not NRM. 44, 45 Pre-HSCT frailty is associated with increased incidence of relapse. In a prospective study of patients aged 50 years or more, pre-HSCT frailty was associated with increased incidence of disease relapse irrespective of age. Among patients in partial or complete remission, while not statistically significant, pre-HSCT frailty was associated with increased relapse. 19 This may imply that patients of any age with high risk or residual disease at the time of HSCT are more likely to be frail, by virtue of pre-HSCT treatment-induced accelerated physiologic aging. However, by the frailty phenotype model (Figure 1 ) disease risk and frailty can exist independently. While frailty assessment can complement HCT-CI in predicting NRM, the DRI is a well validated tool that provides supplementary information regarding incidence of relapse. Hence, we can improve the ability of PTA to predict OS by combining frailty assessment with HCT-CI and DRI.
Frailty assessments have been validated to predict increased mortality and institutionalization risk in the general geriatric population. [46] [47] [48] They have been shown to predict mortality in geriatric oncology patients. 49, 50 In HSCT recipients, frailty assessment remains a scarcely utilized tool.
Frailty assessment Frailty phenotype. The frailty phenotype described by Fried et al. 51 delineates physical frailty as a distinct entity and is devised to capture the clinical manifestations of diminishing physiologic reserve. Physical frailty is distinct yet causally interrelated with disability and comorbidity. 52 While the presence of comorbidity increases the risk for frailty and disability, measuring comorbidity alone may not identify individuals vulnerable to adverse outcomes. Similarly, not all disabled individuals are frail or have comorbidities. Frailty could exist without the presence of disability or comorbidity (Figure 1) .
Frailty is diagnosed when three or more of five phenotypic criteria are met-weakness as measured by low grip strength, slowed walking speed, low level of physical activity, low energy or self-reported exhaustion and unintentional weight loss (Table 1) . Pre-frailty, which has a high risk of progression to frailty, is identified when one or two criteria are present. In the general geriatric population, Fried et al. 51 have demonstrated that the frailty phenotype independently predicted adverse outcomes, which included worsened mobility or disability and death.
When the five frailty phenotype criteria along with cognitive impairment and depressive symptoms were evaluated, slow gait speed was the strongest predictor of chronic disability and longterm nursing home stay. Low physical activity was the strongest predictor of mortality. 53 This suggests that assessing physical mobility might be complementary to HCT-CI and KPS scores during PTA (Table 2) . Frailty index. Biologic aging and therefore frailty has been attributed to accumulation of deficits. 54 Frailty Index (FI) is the ratio of the number of deficits present in a person to the total number of potential deficits evaluated. 46, 55 Increase in FI is associated with increased risk of institutionalization and mortality. [46] [47] [48] It can be operationalized using comprehensive geriatric assessment (CGA) which is a multidimensional, multidisciplinary assessment of an older individual's functional status, comorbidity, nutritional status, cognitive ability, social support and medication use. Various components of the CGA can predict morbidity and mortality in elderly cancer patients. 50, 56 CGA is also able to detect previously unknown or sub-optimally treated conditions with implications for interventions in order to reverse conditions that might pose an obstacle to HSCT. 57 Muffly et al. Geriatric HSCT patients 20 
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Abbreviations: ADL = activities of daily living; HSCT = hematopoietic stem cell transplantation; IADL = instrumental activities of daily living; NRM = non-relapse mortality; OS = overall survival; 6MWT = six-minute walk test; SPPB = short physical performance battery; TUG = timed up and go. Older HSCT recipients 20, 58 OS OS FI Ratio of the number of deficits present in a person to the total number of potential deficits evaluated. Pre-HSCT assessment of frailty A Hegde and HS Murthy activities of daily living, slow walk speed, poor mental health status and elevated C-reactive protein were significantly associated with inferior OS. Hazard ratios for these measures were higher for patients over the age of 60 years. Despite their apparent advantages, CGA and FI are instruments that are lengthy, time consuming, and expensive, both of which have not been standardized or validated in the pre-HSCT setting. In an attempt to simplify the process, Clegg et al. 59 utilized electronic health record data to develop and validate an electronic frailty index (eFI). In this study, only 36 deficits were counted as opposed to 92 in the original frailty index model. Patients aged 65-95 years were classified as fit (eFI 0-0.12), mildly frail (eFI 0.12-0.24), moderately frail (eFI 0.24-0.36) and severely frail (eFI 40.36). The risk of mortality, unplanned hospitalization, length of hospitalization and admission to nursing home increased across all degrees of frailty at 1, 3 and 5 years when compared with fit individuals. While eFI is promising, the lack of uniformity in EHR systems in the US and furthermore, Table 4 . Pre-CGA Screening Tools studied in geriatric oncology Scale Description GFI 103, 104 Questionnaire that screens for loss of function in four domains-physical, cognitive, social and psychological. VES-13 104, 105 Questionnaire about self-rated health-status, physical fitness and need for assistance with activities. aCGA 104 Questionnaire that includes questions about three domains-functional status, cognitive status and depression. fTRST 106 Five-item questionnaire to screen for geriatric profile. G8 103, 104, 106 Questionnaire developed as a screening tool for CGA.
Abbreviations: aCGA = Abbreviated Comprehensive Geriatric Assessment; fTRST = Flemish Triage Risk Screening Tool; GFI = Groningen Frailty Index; VES-13 = Vulnerable Elders-13 Survey. Pre-HSCT assessment of frailtythe unavailability of EHR in many other countries limits its use (Table 3) . Alternatively, it may be advantageous to develop screening tools to detect vulnerable individuals in need of CGA (Table 4) . Although some available pre-CGA screening tools are reasonably sensitive in detecting frailty, none have acceptable negative predictive value. 60, 61 Biomarkers of frailty. Cellular senescence induced by high intensity chemotherapy and radiation exposure during HSCT can induce production of pro-inflammatory cytokines also known as senescence associated secretory phenotype. 25 High pre-transplant C-reactive protein is associated with worse OS in HSCT recipients. 20, 62 Other biomarkers of inflammation such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), insulin growth factor-1 (IGF-1) are associated with increased mortality in the general geriatric population. 63, 64 In the general oncology population, inflammation-based prognostic scores such as the modified Glasgow prognostic score and prognostic index are predictive of reduced cancer-specific survival, independent of age. 65 In HSCT recipients, peripheral blood T-cell p16 INK4a , a molecular marker of cellular senescence increases in response to high dose chemotherapy and both autologous as well as allogeneic HSCT. 23, 66 The evidence for association of shortened telomere length which is considered to be a biomarker of aging, with outcomes in HSCT recipients remains inconsistent. 67, 68 Prospective studies are needed to determine if biomarkers can effectively detect frailty and whether they do so independently or in conjunction with other PTA measures.
Interventions
The first step before intervention is identifying frailty. Impact of interventions may not be apparent if the impairment detected by frailty assessment is not modifiable. For instance, in an undifferentiated group of adult HSCT recipients, a self-directed exercise program and self-directed stress management program had no effect on OS and patient reported outcomes. 69 Selecting individuals most likely to benefit from frailty-specific interventions is likely the key to improving HSCT outcomes.
Patients of all ages stand to benefit from pre-HSCT frailty assessment due to the pervasiveness of frailty and its ageindependent impact on adverse outcomes in HSCT recipients. Frailty assessment can be incorporated into PTA using an algorithmic approach (Figure 2) . Individuals with HCT-CI score ⩾ 3, KPS o 70, high to very high risk DRI and irreversible impairments detected on frailty assessment are potentially at high risk of adverse HSCT outcomes. Since the risk of HSCT outweighs its benefits in this subset of patients, while unfortunate, the intervention would be to defer HSCT and consider alternative therapeutic or palliative options.
Individuals with intermediate HCT-CI score of 1-2 and KPS 70-90, intermediate risk DRI with reversible impairments detected by frailty assessment are the most likely to benefit from interventions. While complex interventions in the geriatric population has shown to reduce hospital admissions, their effect on frailty itself and OS are not well studied. 70 The most convincing evidence of benefit in the general geriatric population and HSCT survivors appears to be for the impact of exercise on physical mobility. In the general geriatric population, multicomponent exercise training helps maintain functional capacity by improving muscle strength, gait and balance. 71, 72 Wiskemann et al. 73 found that a partly supervised exercise intervention that consisted of both resistance and endurance training implemented before, during and after allogeneic HSCT led to significant improvement in fatigue and physical functioning. Combined cognitive and physical training appear to have a sustained long-term benefit in terms of independent living, cognitive and emotional status of elderly individuals. 74 While pharmacologic interventions such as testosterone and growth hormone supplementation may improve muscle mass and physical function in frail elderly men, their side effects negate any such benefit. 75, 76 Since Vitamin D supplementation in the elderly has been shown to improve muscle strength and balance in older individuals, it may be beneficial in preventing or reversing frailty. 77 Early involvement of physical therapy, occupational therapy, psychiatry and neurology for the purpose of physical and cognitive training may help rectify impairments in instrumental activities of daily living, cognition and physical mobility.
Nutritional supplementation in the absence of exercise does not appear to reduce physical frailty. 78 Use of megestrol, a synthetic progestational orexigenic agent led to weight gain in patients with malignancies. 79 A study in nursing home residents aged ⩾ 55 years showed that megestrol led to weight gain, improved appetite and quality of life in elderly nursing home residents but did not impact survival. 80 A study of muscle strength training with and without megestrol showed that megestrol had a detrimental effect on physical function. 81 Other orexigenic agents such as dronabinol and cyproheptadine do not lead to weight gain and are associated with significant adverse effects. [82] [83] [84] Weight loss can be multifactorial, due to social isolation, depression, need for assistance with meal preparation and feeding, medications and comorbidities. Promptly addressing the underlying cause of weight loss with the aid of nutritionists, other medical subspecialties, social services and caregivers may lead to more success with reversing weight loss.
Palliative care has been shown to improve symptoms, quality of life and survival in cancer patients. [85] [86] [87] [88] [89] Integration of palliative care during HSCT led to smaller decline in quality of life, lesser increase in depression and less anxiety at 2 weeks post HSCT than controls. At 3 months post HSCT, quality of life and depression were significantly better in HSCT recipients who received palliative care. 90 A study of early pre-HSCT palliative care showed that it was feasible, improved mood and provided a sense of hope to participants. 91 Early palliative care during PTA for patients with impairments in CGA could improve quality of life, symptom control and reduce mood disturbances that contribute to frailty.
CONCLUSION
Frailty syndrome is prevalent across all ages, both before and after HSCT and is associated with increased mortality. Various frailty assessment tools have been validated for use in the general geriatric population to predict adverse outcomes. These could augment the existing methods of pre-HSCT assessment to identify individuals of all ages and particularly the elderly at risk for adverse outcomes. A multidisciplinary approach to address reversible impairments found on frailty assessment could help improve HSCT outcomes.
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